{"id":984621,"date":"2026-07-24T08:50:05","date_gmt":"2026-07-24T12:50:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-demonstrates-renal-nerve-sensing-and-neural-activity-change-in-preclinical-study\/"},"modified":"2026-07-24T08:50:05","modified_gmt":"2026-07-24T12:50:05","slug":"autonomix-medical-demonstrates-renal-nerve-sensing-and-neural-activity-change-in-preclinical-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-demonstrates-renal-nerve-sensing-and-neural-activity-change-in-preclinical-study\/","title":{"rendered":"Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study"},"content":{"rendered":"
\n

\n Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation<\/i>\n <\/p>\n

\n THE WOODLANDS, TX, July 24, 2026 (GLOBE NEWSWIRE) — <\/b>
\n Autonomix Medical, Inc.<\/a>\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced positive results from a preclinical study demonstrating the ability of its proprietary neural sensing platform to detect, localize and confirm changes in renal neural activity.<\/p>\n

The study successfully demonstrated Autonomix’s ability to identify neural signals associated with nerve activity along the renal artery and surrounding tissue, providing direct physiological feedback before and after targeted ablation. The findings support further development of the Company’s neural sensing platform for physiology-guided renal denervation procedures.<\/p>\n

In the study, the Autonomix catheter was deployed endovascularly within the renal arteries of an animal subject. Neural activity was recorded across multiple anatomical locations, with distinct signal signatures identified and consistent neural activity patterns observed. Following targeted ablation, researchers observed attenuation of previously detected neural signals, supporting the platform’s potential ability to both identify neural targets and assess changes in neural activity following therapy.<\/p>\n

“These findings represent a critical milestone in validating our ability to both sense and localize renal nerve activity,” said Brad Hauser, Chief Executive Officer of Autonomix Medical. “Current renal denervation procedures are performed without direct physiological feedback, requiring physicians to rely primarily on anatomical landmarks rather than physiological information. Our technology has the potential to transform this paradigm by enabling a more precise, data-driven approach to therapy.”<\/p>\n

Mr. Hauser continued, “By providing physicians with actionable neural sensing information throughout the treatment procedure, we believe our platform could help physicians tailor therapy using patient-specific neural information. This proof-of-concept study supports continued development toward clinical applications that incorporate patient-specific neural information to guide therapy.”<\/p>\n

Autonomix’s proprietary platform is designed to provide physiological information not available through conventional renal denervation approaches. Renal denervation has demonstrated clinical promise as a treatment for resistant hypertension, yet outcomes have varied across studies and patient populations. One challenge has been the inability to identify active neural activity and assess changes in that activity during the procedure. Autonomix believes its sensing technology may address this limitation by enabling:<\/p>\n